Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Wermke

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Zentralblatt Fur Chirurgie|August 13, 2024
[Perioperative Targeted Therapy for Operable, Early Stage NSCLC]Samer Etman, Felix Saalfeld, Daniela Aust, et al.
Future Oncology (London, England)|July 11, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomasMartin Wermke, Enriqueta Felip, Valentina Gambardella, et al.
Stem Cell Reports|April 30, 2019
Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential RegulatorCeren Güneş, Maciej Paszkowski-Rogacz, Susann Rahmig, et al.
Oncotarget|June 8, 2018
STK3 is a therapeutic target for a subset of acute myeloid leukemiasAylin Camgoz, Maciej Paszkowski-Rogacz, Shankha Satpathy, et al.
BMC Cancer|May 21, 2022
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studiesUwe Platzbecker, Joerg Chromik, Jan Krönke, et al.
British Journal of Haematology|December 10, 2009
188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantationAnett Lauter, Annette Strumpf, Uwe Platzbecker, et al.
Blood|May 31, 2002
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisChristian Thiede, Christine Steudel, Brigitte Mohr, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 5, 2012
Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantationFelix Bahr, Rebekka Wehner, Uwe Platzbecker, et al.
Clinical Therapeutics|May 31, 2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumorsVictor Moreno, Richard Greil, Jeffrey Yachnin, et al.
Scientific Reports|August 9, 2020
Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenograftsNandini Asokan, Stephan Daetwyler, Stefanie N Bernas, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Zentralblatt Fur Chirurgie|August 13, 2024
[Perioperative Targeted Therapy for Operable, Early Stage NSCLC]Samer Etman, Felix Saalfeld, Daniela Aust, et al.
Future Oncology (London, England)|July 11, 2022
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomasMartin Wermke, Enriqueta Felip, Valentina Gambardella, et al.
Stem Cell Reports|April 30, 2019
Comparative RNAi Screens in Isogenic Human Stem Cells Reveal SMARCA4 as a Differential RegulatorCeren Güneş, Maciej Paszkowski-Rogacz, Susann Rahmig, et al.
Oncotarget|June 8, 2018
STK3 is a therapeutic target for a subset of acute myeloid leukemiasAylin Camgoz, Maciej Paszkowski-Rogacz, Shankha Satpathy, et al.
BMC Cancer|May 21, 2022
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studiesUwe Platzbecker, Joerg Chromik, Jan Krönke, et al.
British Journal of Haematology|December 10, 2009
188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantationAnett Lauter, Annette Strumpf, Uwe Platzbecker, et al.
Blood|May 31, 2002
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisChristian Thiede, Christine Steudel, Brigitte Mohr, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 5, 2012
Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantationFelix Bahr, Rebekka Wehner, Uwe Platzbecker, et al.
Clinical Therapeutics|May 31, 2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumorsVictor Moreno, Richard Greil, Jeffrey Yachnin, et al.
Scientific Reports|August 9, 2020
Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenograftsNandini Asokan, Stephan Daetwyler, Stefanie N Bernas, et al.
Pageof 9